Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
March 04 2021 - 10:54AM
Edgar (US Regulatory)
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of March 2021
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
Designation of EU home member state for EU securities regulation
purposes
4 March 2021 15:00 GMT
Designation of EU home member state for EU securities regulation
purposes
Following the exit of the United Kingdom from the European
Union, AstraZeneca PLC (AstraZeneca) announces that it
has selected Sweden as its home member state for EU securities
regulation purposes pursuant to the Swedish Securities Market Act
(Sw. lagen (2007.528) om
värdepappersmarknaden).
AstraZeneca will file certain regulatory information with the
Swedish Financial Supervisory Authority in accordance with
applicable EU and Swedish law. These filings will be in addition to
AstraZeneca's continuing disclosure obligations under applicable UK
law, including the UK Disclosure Guidance and Transparency Rules.
AstraZeneca's status as a UK PLC and the location of its
headquarters in the United Kingdom remain unchanged.
AstraZeneca's selection of Sweden as its home member state for EU
securities regulation purposes also means that certain continuing
notification obligations pursuant to Swedish law will apply to
dealings or interests in AstraZeneca securities in addition to the
existing obligations under the UK Disclosure Guidance and
Transparency Rules. These include notifications as soon as holdings
of financial instruments or short positions reach, exceed or go
below certain thresholds. AstraZeneca recommends its shareholders
to inform themselves about the notification obligations under
Swedish law and to consult with their legal advisers in case of any
questions.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global,
science-led biopharmaceutical company that focuses on the
discovery, development and commercialisation of prescription
medicines, primarily for the treatment of diseases in three therapy
areas - Oncology, Cardiovascular, Renal & Metabolism, and
Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca
operates in over 100 countries and its innovative medicines are
used by millions of patients worldwide. Please
visit astrazeneca.com and
follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
Additional information
This information is information that AstraZeneca PLC is obliged to
make public pursuant to the Swedish Securities Market Act. The
information was submitted for publication, through the agency of
the contact persons set out above, at 15:00 on 4 March
2021.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date:
04 March
2021
|
By: /s/
Adrian Kemp
|
|
Name:
Adrian Kemp
|
|
Title:
Company Secretary
|
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Aug 2024 to Sep 2024
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Sep 2023 to Sep 2024